24.58
price up icon0.70%   0.1642
 
loading
Schlusskurs vom Vortag:
$24.42
Offen:
$24.6
24-Stunden-Volumen:
819.16K
Relative Volume:
0.65
Marktkapitalisierung:
$15.77B
Einnahmen:
$2.62B
Nettoeinkommen (Verlust:
$966.70M
KGV:
16.39
EPS:
1.5004
Netto-Cashflow:
$1.09B
1W Leistung:
+5.49%
1M Leistung:
+12.80%
6M Leistung:
+10.07%
1J Leistung:
-8.99%
1-Tages-Spanne:
Value
$24.46
$24.84
1-Wochen-Bereich:
Value
$23.22
$24.84
52-Wochen-Spanne:
Value
$17.23
$27.94

Genmab Adr Stock (GMAB) Company Profile

Name
Firmenname
Genmab Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
2,638
Name
Twitter
@Genmab
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
GMAB's Discussions on Twitter

Vergleichen Sie GMAB mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GMAB
Genmab Adr
24.58 14.40B 2.62B 966.70M 1.09B 1.5004
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
396.71 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
592.25 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
457.04 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
662.77 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
312.73 37.96B 3.81B -644.79M -669.77M -6.24

Genmab Adr Stock (GMAB) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-01 Herabstufung Bernstein Mkt Perform → Underperform
2025-03-11 Hochstufung William Blair Mkt Perform → Outperform
2025-02-13 Hochstufung Leerink Partners Market Perform → Outperform
2024-10-08 Eingeleitet Redburn Atlantic Buy
2024-09-04 Fortgesetzt Morgan Stanley Equal-Weight
2024-08-20 Herabstufung JP Morgan Overweight → Neutral
2024-07-15 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2024-02-23 Hochstufung BMO Capital Markets Market Perform → Outperform
2024-01-22 Herabstufung Citigroup Neutral → Sell
2023-12-06 Hochstufung UBS Neutral → Buy
2023-11-10 Hochstufung Deutsche Bank Hold → Buy
2023-11-08 Hochstufung DNB Markets Sell → Buy
2023-10-18 Eingeleitet Exane BNP Paribas Underperform
2023-09-06 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-08-24 Eingeleitet BTIG Research Buy
2023-07-14 Eingeleitet HSBC Securities Buy
2023-05-31 Eingeleitet UBS Neutral
2023-05-12 Eingeleitet Morgan Stanley Underweight
2022-12-20 Herabstufung Citigroup Buy → Neutral
2022-11-14 Eingeleitet William Blair Mkt Perform
2022-11-11 Herabstufung Deutsche Bank Buy → Hold
2022-06-24 Eingeleitet BMO Capital Markets Market Perform
2022-05-02 Eingeleitet Cowen Market Perform
2022-03-16 Hochstufung UBS Neutral → Buy
2022-01-31 Hochstufung H.C. Wainwright Neutral → Buy
2022-01-03 Herabstufung Guggenheim Buy → Neutral
2021-12-01 Eingeleitet Berenberg Sell
2021-09-16 Herabstufung Jefferies Buy → Hold
2021-09-07 Herabstufung Morgan Stanley Equal-Weight → Underweight
2021-08-24 Herabstufung H.C. Wainwright Buy → Neutral
2021-04-20 Eingeleitet Deutsche Bank Buy
2021-01-19 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-09-23 Herabstufung Bryan Garnier Neutral → Sell
2020-09-08 Eingeleitet SVB Leerink Mkt Perform
2020-06-25 Herabstufung Credit Suisse Outperform → Neutral
2020-04-23 Eingeleitet Credit Suisse Outperform
2020-02-24 Bestätigt H.C. Wainwright Buy
2020-01-13 Eingeleitet SunTrust Buy
2019-12-12 Herabstufung Deutsche Bank Buy → Hold
2019-09-13 Hochstufung BofA/Merrill Neutral → Buy
2019-09-12 Hochstufung JP Morgan Neutral → Overweight
2019-08-12 Eingeleitet Guggenheim Buy
2019-08-12 Eingeleitet Morgan Stanley Overweight
2019-08-12 Eingeleitet RBC Capital Mkts Outperform
Alle ansehen

Genmab Adr Aktie (GMAB) Neueste Nachrichten

pulisher
Aug 20, 2025

IBD Rating Upgrades: WR Berkley Flashes Improved Technical Strength - inkl

Aug 20, 2025
pulisher
Aug 19, 2025

Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily

Aug 19, 2025
pulisher
Aug 19, 2025

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors - GlobeNewswire Inc.

Aug 19, 2025
pulisher
Aug 18, 2025

What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World

Aug 18, 2025
pulisher
Aug 18, 2025

BioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark - inkl

Aug 18, 2025
pulisher
Aug 15, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by LPL Financial LLC - Defense World

Aug 15, 2025
pulisher
Aug 11, 2025

What is William Blair’s Forecast for Genmab A/S Q3 Earnings? - Defense World

Aug 11, 2025
pulisher
Aug 09, 2025

Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade - MSN

Aug 09, 2025
pulisher
Aug 08, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Market Game Changer? - The Globe and Mail

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech and Genmab’s Promising Colorectal Cancer Study: A Potential Game-Changer? - TipRanks

Aug 08, 2025
pulisher
Aug 07, 2025

GMAB: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com

Aug 07, 2025
pulisher
Aug 07, 2025

Genmab and BioNTech’s Promising Cancer Study: A Potential Game-Changer? - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Aug 07, 2025
pulisher
Aug 06, 2025

Genmab and BioNTech’s Innovative Cancer Trial: A Potential Game-Changer? - The Globe and Mail

Aug 06, 2025
pulisher
Aug 05, 2025

Genmab and BioNTech SE’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks

Aug 05, 2025
pulisher
Aug 02, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

Aug 02, 2025
pulisher
Jul 24, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stake Lessened by Cerity Partners LLC - Defense World

Jul 24, 2025
pulisher
Jul 24, 2025

Genmab and BioNTech Launch Promising Study for Advanced Colorectal Cancer Treatment - The Globe and Mail

Jul 24, 2025
pulisher
Jul 23, 2025

Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN

Jul 23, 2025
pulisher
Jul 22, 2025

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High? - Zacks Investment Research

Jul 22, 2025
pulisher
Jul 19, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Envestnet Asset Management Inc. - Defense World

Jul 19, 2025
pulisher
Jul 17, 2025

Genmab Bets On Antibody Innovations As Royalties Rule The Day - Finimize

Jul 17, 2025
pulisher
Jul 16, 2025

Genmab A/S FY2025 EPS Estimate Increased by William Blair - Defense World

Jul 16, 2025
pulisher
Jul 11, 2025

Genmab AS (ADR) (US3723032062.SG) latest stock news and headlines - yahoo.co

Jul 11, 2025
pulisher
Jul 11, 2025

Genmab A/S (NASDAQ:GMAB) Price Target Raised to $46.00 - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 10, 2025
pulisher
Jul 09, 2025

Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - The Globe and Mail

Jul 09, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World

Jul 08, 2025
pulisher
Jul 08, 2025

Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks

Jul 08, 2025
pulisher
Jul 06, 2025

Mirae Asset Global Investments Co. Ltd. Cuts Stock Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jul 06, 2025
pulisher
Jun 30, 2025

Envestnet Portfolio Solutions Inc. Sells 6,066 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jun 30, 2025
pulisher
Jun 19, 2025

GAMMA Investing LLC Boosts Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB) - Defense World

Jun 19, 2025
pulisher
Jun 02, 2025

Why Genmab Stock Smashed It On Monday - Barchart.com

Jun 02, 2025
pulisher
May 12, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

May 12, 2025
pulisher
May 09, 2025

Applied Dna Sciences Inc (APDN)’s Day in Review: Closing at 0.85, Down by -2.41 - DWinneX

May 09, 2025
pulisher
May 09, 2025

Stock Surge: Genmab ADR (GMAB) Closes at 19.42, Marking a -5.73 Increase/Decrease - DWinneX

May 09, 2025
pulisher
May 09, 2025

Market Momentum Report: Evercore Inc (EVR)’s Positive Close at 216.74 - DWinneX

May 09, 2025
pulisher
Apr 23, 2025

Investing in Take-Two Interactive Software, Inc (TTWO) Is Getting More Attractive - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Investing in Genmab ADR (GMAB): What You Must Know - knoxdaily.com

Apr 23, 2025
pulisher
Apr 23, 2025

Nucor Corp (NUE) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 23, 2025
pulisher
Apr 17, 2025

EWTX Stock Sees Surge of Approximately 4.24% in Last Five Days - knoxdaily.com

Apr 17, 2025
pulisher
Apr 16, 2025

GMAB or RGEN: Which Is the Better Value Stock Right Now? - Yahoo Finance

Apr 16, 2025
pulisher
Apr 16, 2025

Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance

Apr 16, 2025

Finanzdaten der Genmab Adr-Aktie (GMAB)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$85.39
price down icon 1.29%
$26.71
price up icon 2.81%
$110.98
price up icon 0.35%
$131.37
price down icon 0.87%
biotechnology ONC
$312.73
price down icon 0.35%
Kapitalisierung:     |  Volumen (24h):